news
EU approves Roche’s Avastin for platinum-resistant recurrent ovarian cancer
6 August 2014 | By Roche
First new treatment option for women in Europe in more than 15 years for most difficult to treat form of ovarian cancer...
List view / Grid view
Roche
news
Roche to acquire Santaris Pharma to expand discovery and development of RNA-targeting medicines
5 August 2014 | By Roche
Roche announced that it has agreed to acquire Santaris Pharma, a privately held biopharmaceutical company based near Copenhagen, Denmark...
news
Roche’s Gazyvaro approved in Europe for patients with the most common type of leukemia
29 July 2014 | By Roche
Roche announced that the European Commission has approved Gazyvaro (obinutuzumab) in combination with chlorambucil chemotherapy...
news
AstraZeneca and Roche announce partnership to develop companion diagnostic test for AZD9291
28 July 2014 | By AstraZeneca
AstraZeneca announced it has entered into collaboration with Roche to develop a plasma-based companion diagnostic test to support AZD9291...
news
Roche with good half year performance
24 July 2014 | By Roche
Pharmaceutical giant Roche delivers its first-half results for 2014...
news
Roche announces phase II clinical results of crenezumab in Alzheimer’s disease
17 July 2014 | By Roche
Roche presented data from two phase II studies investigating whether crenezumab can delay cognitive and functional decline in people with mild-to-moderate Alzheimer’s disease...
news
FDA grants Roche’s Avastin Priority Review for certain types of cervical cancer
15 July 2014 | By Roche
Roche announced that the U.S. Food and Drug Administration has accepted the company's supplemental Biologics License Application and granted Priority Review for Avastin (bevacizumab) plus chemotherapy for the treatment of women with persistent, recurrent or metastatic cervical cancer...
news
Roche’s investigational medicine cobimetinib, used in combination with Zelboraf (vemurafenib), helped people with advanced melanoma live significantly longer without their disease worsening
14 July 2014 | By Roche
Roche announced that the Phase III coBRIM study met its primary endpoint...
news
Japan becomes first country to approve Roche’s alectinib for people with a specific form of advanced lung cancer
4 July 2014 | By Roche
Data showed that over 90 percent of Japanese people in the study responded to treatment with alectinib...
news
Roche announces definitive agreement to acquire Seragon Pharmaceuticals
2 July 2014 | By Roche
Acquisition of Phase I program offers a potential new approach for hormone receptor-positive breast cancer...
news
Roche launches fully automated urine testing analyzer for enhanced result reliability and staff safety
30 June 2014 | By Roche
Roche announced the launch of cobas® 6500, a fully automated urine testing system that consists of two modular analyzers combining urine strip testing and digital urinary microscopy...
news
CHMP recommends EU approval of Roche’s Avastin for platinum-resistant recurrent ovarian cancer
27 June 2014 | By Roche
Roche announced that the EU Committee for Medicinal Products for Human Use recommended that the European Commission approve the use of Avastin® (bevacizumab)...
news
Roche acquires Genia Technologies to strengthen next generation sequencing pipeline
2 June 2014 | By Roche
Roche announced the acquisition of Genia Technologies, Inc. (Genia), a privately held company, based in Mountain View, California, USA...
news
CHMP recommends EU approval of Roche’s Gazyvaro™ for people with chronic lymphocytic leukemia
23 May 2014 | By Roche
Roche announced that the EU Committee for Medicinal Products for Human Use recommended that the European Commission approve Gazyvaro in combination with chlorambucil for the treatment of adult patients with previously untreated chronic lymphocytic leukemia...
news
Roche invests 120 million Swiss francs in new production facilities at Basel
19 May 2014 | By Roche
Roche announced plans to invest a total of 120 million Swiss francs in the construction of new production facilities in Building 50, an existing building at its Basel site...
